Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

76631

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Transplant Surgery
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what they are doing to promote organ transplants.
	tabling member printed	Lord Bourne of Aberystwyth
	uin	HL973
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The six years between April 2008 and April 2014 have seen a strengthening of the donation programme; increasing donation rates by 63% and transplant rates by 47%. The number of people registering for organ donation has increased by over 3 million since 2010 to over 20 million.</p><p> </p><p>A new seven year United Kingdom-wide organ donation and transplantation strategy <em>Taking Organ Transplantation to 2020: A UK strategy</em>, was published by NHS Blood and Transplant (NHSBT) in July 2013. The strategy sets out proposed action to increase consent rates, optimise donation and increase transplants.</p><p> </p><p>NHSBT continues to raise the profile of organ donation through a number of other ways. For example, people can join the Organ Donor Register online, through Facebook, by phone, post, registering with a general practitioner, a Boots pharmacy loyalty card or when applying for a passport. More people from Black, Asian and Minority Ethnic communities are needed to register on the Organ Donor Register and the recently launched Peer Educator Project, sponsored by the Department, training peer educators from the Pakistani Muslim community in Birmingham, is an example of action in this area. The Parliamentary Under-Secretary of State for Public Health (Jane Ellison) wrote to all Members during the National Transplant Week to raise the profile and benefits of organ donation and transplantation. The British Kidney Patient Association and NHS Blood and Transplant also held a reception in Parliament.</p><p> </p> answering member printed Earl Howe question first answered 23/07/2014 14:20:53 answering member 2000 label Biography information for Earl Howe
	tabling member	4282 label Biography information for Lord Bourne of Aberystwyth

76626

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Meningitis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is the timetable for the procurement and introduction of the meningitis B vaccine.
	tabling member printed	Baroness Corston
	uin	HL968
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>We are committed to introducing this vaccine as soon as practicable, in line with the Joint Committee on Vaccination and Immunisation’s recommendation, subject to the manufacturer offering the vaccine at a cost-effective price.</p> answering member printed Earl Howe question first answered 23/07/2014 12:36:57 answering member 2000 label Biography information for Earl Howe
	tabling member	215 label Biography information for Baroness Corston

78233

	registered interest
	date	15/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Motor Neurone Disease
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government how much has been spent on research into the causes of, and treatment and cure for, motor neurone disease by all publicly funded departments and bodies in each year since 2010.
	tabling member printed	Lord Foulkes of Cumnock
	uin	HL1128
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p> </p><p>The following table shows expenditure on research on motor neurone disease (MND) and amyotrophic lateral sclerosis (ALS - a sub type of MND) by the Medical Research Council and by the National Institute for Health Research (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p>£ million</p><p><em> </em></p><table><tbody><tr><td><p> </p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>n/a</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.6</p></td><td><p>4.6</p></td><td><p>4.8</p></td><td><p>n/a</p></td></tr></tbody></table><p> </p><p>Total spend by the NIHR on MND/ALS is higher than this because expenditure by the NIHR Clinical Research Network (CRN) on this topic cannot be disaggregated from total CRN expenditure.</p> answering member printed Earl Howe question first answered 23/07/2014 12:25:56 answering member 2000 label Biography information for Earl Howe
	tabling member	579 label Biography information for Lord Foulkes of Cumnock

78228

	registered interest
	date	15/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Sickle Cell Diseases
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is their strategy towards the treatment of sickle cell disease.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL1123
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The vast majority of sickle cell disease (SCD) affected children born in England are identified by the NHS Sickle Cell and Thalassaemia Screening programme, and other patients may present through migration or late diagnosis</p><p> </p><p>SCD is a lifelong condition, and NHS England provides high quality care for patients with SCD as part of its specialised commissioning responsibilities. NHS England’s Haemaglobinopathies service specification clearly sets out what providers must have in place for providers to offer evidence-based, safe and effective services.</p><p> </p><p>Although SCD patient care will be coordinated by a Specialist Haemoglobinopathy Centre (SHC), the majority of care may be delivered outside of the SHC by a range of providers. The configuration of care provision will be based on local prevalence, expertise and availability of service providers, and this may include acute hospitals, community care, primary care and the voluntary sector.</p><p> </p><p>Information concerning the number of SCD patients in each parliamentary constituency is not collected. However, NHS England’s service specification sets out that there are around 15,000 patients with SCD living in England at present. In England SCD occurs predominantly, but not exclusively, in ethnic minority communities. It is the most common inherited condition in England and around 350 babies with SCD are born each year.</p><p> </p> answering member printed Earl Howe grouped question UIN HL1121 HL1122 question first answered 23/07/2014 12:31:23 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

78227

	registered interest
	date	15/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Sickle Cell Diseases
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what trends they have identified in the prevalence of sickle cell disease in the United Kingdom over the last 10 years.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL1122
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The vast majority of sickle cell disease (SCD) affected children born in England are identified by the NHS Sickle Cell and Thalassaemia Screening programme, and other patients may present through migration or late diagnosis</p><p> </p><p>SCD is a lifelong condition, and NHS England provides high quality care for patients with SCD as part of its specialised commissioning responsibilities. NHS England’s Haemaglobinopathies service specification clearly sets out what providers must have in place for providers to offer evidence-based, safe and effective services.</p><p> </p><p>Although SCD patient care will be coordinated by a Specialist Haemoglobinopathy Centre (SHC), the majority of care may be delivered outside of the SHC by a range of providers. The configuration of care provision will be based on local prevalence, expertise and availability of service providers, and this may include acute hospitals, community care, primary care and the voluntary sector.</p><p> </p><p>Information concerning the number of SCD patients in each parliamentary constituency is not collected. However, NHS England’s service specification sets out that there are around 15,000 patients with SCD living in England at present. In England SCD occurs predominantly, but not exclusively, in ethnic minority communities. It is the most common inherited condition in England and around 350 babies with SCD are born each year.</p><p> </p> answering member printed Earl Howe grouped question UIN HL1121 HL1123 question first answered 23/07/2014 12:31:24 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

78226

	registered interest
	date	15/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Sickle Cell Diseases
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government how many patients in each parliamentary constituency have sickle cell disease.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL1121
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The vast majority of sickle cell disease (SCD) affected children born in England are identified by the NHS Sickle Cell and Thalassaemia Screening programme, and other patients may present through migration or late diagnosis</p><p> </p><p>SCD is a lifelong condition, and NHS England provides high quality care for patients with SCD as part of its specialised commissioning responsibilities. NHS England’s Haemaglobinopathies service specification clearly sets out what providers must have in place for providers to offer evidence-based, safe and effective services.</p><p> </p><p>Although SCD patient care will be coordinated by a Specialist Haemoglobinopathy Centre (SHC), the majority of care may be delivered outside of the SHC by a range of providers. The configuration of care provision will be based on local prevalence, expertise and availability of service providers, and this may include acute hospitals, community care, primary care and the voluntary sector.</p><p> </p><p>Information concerning the number of SCD patients in each parliamentary constituency is not collected. However, NHS England’s service specification sets out that there are around 15,000 patients with SCD living in England at present. In England SCD occurs predominantly, but not exclusively, in ethnic minority communities. It is the most common inherited condition in England and around 350 babies with SCD are born each year.</p><p> </p> answering member printed Earl Howe grouped question UIN HL1122 HL1123 question first answered 23/07/2014 12:31:24 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

78225

	registered interest
	date	15/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the care received by girls suffering from vaccine injury related to the human papilloma virus vaccine.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL1120
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The Department has not made such an assessment. The Medicines and Healthcare products Regulatory Agency (MHRA), has closely evaluated the safety of Human papillomavirus (HPV) vaccine since introduction in the national immunisation programme in 2008. In September 2012 the MHRA sought advice from the Commission on Human Medicines (CHM) on the safety of HPV vaccine, which advised that no new safety concerns have been identified and the balance of risks and benefits of the vaccine remains positive.</p><p><strong> </strong></p><p>The MHRA reviews are available on the MHRA website:</p><p> </p><p><a href="http://www.mhra.gov.uk/HPVvaccine" target="_blank">www.mhra.gov.uk/HPVvaccine</a>.</p><p> </p><p>The MHRA continues to closely evaluate the safety of Gardasil HPV vaccine since it replaced Cervarix in 2012.</p> answering member printed Earl Howe question first answered 23/07/2014 12:32:18 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

78224

	registered interest
	date	15/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what plans, if any, they have to introduce the human papilloma virus vaccine for boys.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL1119
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI), the Government’s expert advisers on immunisation matters, has set up a human papillomavirus (HPV) sub-committee to consider a number of key issues around HPV vaccination, including vaccinating men who have sex with men (MSM) and potential extension of the current programme to include adolescent boys.</p><p> </p><p>The HPV sub-committee will report its findings to the JCVI following consideration of studies by Public Health England on the impact and cost-effectiveness of extending HPV vaccination to MSM or adolescent boys. It is expected that the MSM modelling study will be completed at the end of 2014 at the earliest, and the adolescent boys modelling study will be completed at the end of 2015 at the earliest</p><p><strong> </strong></p><p>The Department will consider carefully the advice from the JCVI once it has completed its assessment.</p> answering member printed Earl Howe question first answered 23/07/2014 12:33:02 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

77811

	registered interest
	date	14/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is their response to the analysis by Diabetes UK of the increasing diagnosis of type 2 diabetes and the implications for the National Health Service budget.
	tabling member printed	Lord Harrison
	uin	HL1108
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>In January 2014, NHS England published the Action for Diabetes plan, which sets out how it intends to improve outcomes for people with, and at risk of, diabetes in England. The report acknowledges that type 2 diabetes is estimated to have cost the United Kingdom £8.8 billion in direct costs in 2010-2011 and that these costs are set to rise.</p><p> </p><p>The action that NHS England is taking and will take to drive the prevention of Type 2 diabetes and earlier diagnosis of all diabetes and support better management of diabetes in primary care includes:</p><p> </p><p>- Developing general practitioner contracts and incentives;</p><p>- working with primary care services to trial and roll out case-finding and decision-support tools in primary care to support earlier diagnosis; and</p><p>working with Public Health England to roll out the NHS Health Check programme.</p> answering member printed Earl Howe question first answered 23/07/2014 12:35:21 answering member 2000 label Biography information for Earl Howe
	tabling member	2488 label Biography information for Lord Harrison

77802

	registered interest
	date	14/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the risks associated with human papilloma virus vaccines.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL1099
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) has closely evaluated the safety of human papillomavirus (HPV) vaccine since it was introduced into the national immunisation programme in 2008. This has involved continual review of suspected side effects reported via the Yellow Card Scheme, evaluation of safety data from other countries and the worldwide medical literature as well as use of the Clinical Practice Research Datalink (CPRD) to further evaluate any potential safety signals.</p><p> </p><p>The MHRA has sought independent expert scientific advice from the Commission on Human Medicines (CHM) on the emerging safety experience with HPV vaccines. Details of the MHRA safety reviews, endorsed by CHM, can be found at:</p><p> </p><p>www.mhra.gov.uk/HPVvaccine.</p><p> </p><p>Information on the safety of vaccines and reports of suspected side effects from the MHRA are also regularly shared with the Joint Committee on Vaccination and Immunisation to inform immunisation policy.</p><p> </p><p>As with any vaccine or medicine, HPV vaccine may cause side effects in some people and these risks are described in the product information (the Summary of Product Characteristics for healthcare professionals and the Patient Information Leaflet). Any potential side effects are outweighed by the expected benefits in protecting against the illness and mortality associated with infection with the human papillomaviruses covered by the vaccine.</p> answering member printed Earl Howe question first answered 23/07/2014 12:36:11 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath